Twenty five cases of advanced postmenopausal breast cancer patients were treated with bisbromoacetyl hexestrol 3 CR and 5 PR were achieved. The response rate was 32 %, and the average duration of remission 6 months. Vaginal bleeding was seen in 9 cases, 4 of whom were compelled to discontinue treatment.
Get full access to this article
View all access options for this article.
References
1.
LingY.H., HuaZ., SunS.Y., LiangY.Y.: Absorption, distribution and excretion of (carboxy-14C) bisbromoacetil hexestrol.Acta Pharmacologica Sinica, 5: 109–111, 1984.
2.
MiaoT.J., ZhangS.Q.: Treatment of prostatic carcinoma with hexestrol dibromoacetate, report of 78 cases.Chinese Journal of Surgery, 18: 502–503, 1980.
3.
PowlesT.J.: Endocrine therapy of breast cancer. In: Breast cancer management.CoombesR.C., PowlesT.J., FordH.T., GagetJ.C. (Eds.), pp. 171–188, Academic Press, London, 1981.
4.
Shanghai Pharmaceutical and Industrial Institute:Antitumor agents. p 168. Shanghai Scientific and Technical Publisher, Shanghai1982.
